ARTELO BIOSCIENCES, INC.
No SEC Form 4 filings for $ARTL in the last 30 days.
See all $ARTL insider activity →Artelo Biosciences (ARTL) said it enrolled the first patient in its Phase 2 DREAM trial of ART27.13, an oral once-daily cannabinoid-receptor agonist for glaucoma or ocular hypertension. The company expects interim results later this year. ART27.13 was originally developed by AstraZeneca and is also in a Phase 2 CAReS trial. ARTL last traded at $0.72.
ARTELO BIOSCIENCES, INC. (ARTL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. artl_8k.htm 0001621221 false 0001621221 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 D
Artelo Biosciences (ARTL) reported positive nonclinical results for ART27.13 in a paclitaxel-induced peripheral neuropathy model. Repeated dosing reduced pain-related behaviors in male and female animals. ART27.13 is in Phase 2 for cancer-related anorexia cachexia syndrome, where interim CAReS data showed weight and activity improvements and safety at up to 1300 µg/day. ARTL shares trade around $1.04.
Over the past 7 days, alphai's AI scored 1 news story mentioning ARTL (ARTELO BIOSCIENCES, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ARTL coverage spans technology, financial news and corporate actions.
First-patient dosing is an early clinical milestone that can improve perceived development momentum, but it is not yet efficacy or safety readout.
The 8-K discloses shareholder approvals that can enable future dilution via increased authorized shares and a >20% issuance under the Square Gate Capital equity purchase agreement.
Positive preclinical pain-endpoint results could improve perceived probability of clinical translation for ART27.13, but it is not yet Phase 2 efficacy data in neuropathy.
Nonclinical efficacy for ART27.13 in chemotherapy-induced peripheral neuropathy could improve perceived pipeline value, but it is preclinical and not a near-term catalyst.
Positive preclinical pain results may strengthen the clinical narrative for ART27.13 and support continued Phase 2 readouts.
alphai scores every news story that mentions ARTL with an AI model for sentiment and relevance, and aggregates insider trades from ARTELO BIOSCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Artelo Biosciences (ARTL) said it enrolled the first patient in its Phase 2 DREAM trial of ART27.13, an oral once-daily cannabinoid-receptor agonist for glaucoma or ocular hypertension. The company expects interim results later this year. ART27.13 was originally developed by AstraZeneca and is also in a Phase 2 CAReS trial. ARTL last traded at $0.72.
2 min readARTELO BIOSCIENCES, INC. (ARTL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. artl_8k.htm 0001621221 false 0001621221 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 D
2 min readArtelo Biosciences (ARTL) reported positive nonclinical results for ART27.13 in a paclitaxel-induced peripheral neuropathy model. Repeated dosing reduced pain-related behaviors in male and female animals. ART27.13 is in Phase 2 for cancer-related anorexia cachexia syndrome, where interim CAReS data showed weight and activity improvements and safety at up to 1300 µg/day. ARTL shares trade around $1.04.
3 min readArtelo Biosciences (ARTL) reported encouraging nonclinical data for ART27.13 in neuropathic pain models tied to cancer supportive care. In paclitaxel-induced peripheral neuropathy animals, repeated dosing reduced neuropathic pain-related behaviors in both sexes. The stock was $1.032 on Nasdaq, down 4.41%.
2 min readArtelo Biosciences (Nasdaq: ARTL) reported nonclinical results for ART27.13, a peripherally restricted cannabinoid agonist, in a paclitaxel-induced peripheral neuropathy model. Repeated dosing reduced neuropathic pain behaviors in male and female animals. The company links this to interim Phase 2 CAReS data in cancer anorexia cachexia syndrome, citing weight and lean mass improvements and a favorable safety profile.
3 min readArtelo Biosciences (Nasdaq: ARTL) reported preclinical mouse data from Stony Brook University showing its FABP5 inhibitor ART26.12 alleviated neuropathic pain after spinal cord injury. The company says results included reduced mechanical hypersensitivity, fewer spontaneous pain behaviors, suppressed nociceptor hyperexcitability, and improved outcomes after oral dosing. ART26.12 is in Phase 1.
4 min readArtelo Biosciences (Nasdaq: ARTL) reported positive preclinical data for ART26.12, its FABP5 inhibitor, in a mouse model of spinal cord injury–induced neuropathic pain. According to the company, FABP5 inhibition reduced mechanical hypersensitivity and spontaneous pain behaviors, suppressed nociceptor hyperexcitability, and improved outcomes after oral dosing; results were presented at the 2026 International Cannabinoid Research Society symposium.
3 min readArtelo Biosciences (ARTL) is terminating its at-the-market (ATM) equity offering agreement with R.F. Lafferty, effective May 18, 2026. The company utilized only a small fraction of the $6.5 million facility, raising approximately $451,527. This decision suggests a shift in Artelo's financing strategy, potentially exploring alternative funding sources given its weak financial performance and analyst sentiment.
3 min readArtelo Biosciences raised $310,000 through two 12% bridge notes from Vanquish Funding Group and Boot Capital to fund working capital. These notes mature on January 15, 2027, and include provisions for an original issue discount, default acceleration, and equity conversion options. Artelo Biosciences will also cover diligence and legal costs for Vanquish.
2 min readART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ...
2 min read
